Supplementary consolidated financial materials for the second quarter of the fiscal year ending March 2027. Revenue was 350.4 hundred million yen (substantial increase YoY), operating income was 115.2 hundred million yen, and quarterly profit was 119.6 hundred million yen. Full-year forecast has been revised; EBITDA is expected to reach 174.6 hundred million yen. Profit growth was driven by strengthened global deployment, consolidation of Torii Pharmaceutical, and transfer of the edaravone business. The pipeline list and foreign exchange assumptions were also updated.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4507","jir_company_name":"Shionogi & Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-10-29","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/10\/4507-20261029-01.pdf","jir_short_summary":"Supplementary consolidated financial materials for the second quarter of the fiscal year ending March 2027. Revenue was 350.4 hundred million yen (substantial increase YoY), operating income was 115.2 hundred million yen, and quarterly profit was 119.6 hundred million yen. Full-year forecast has been revised; EBITDA is expected to reach 174.6 hundred million yen. Profit growth was driven by strengthened global deployment, consolidation of Torii Pharmaceutical, and transfer of the edaravone business. The pipeline list and foreign exchange assumptions were also updated.","jir_summary":"### Performance Overview\nShionogi & Co., Ltd. reported consolidated revenue of 350.4 hundred million yen, operating income of 115.2 hundred million yen, and quarterly profit of 119.6 hundred million yen for the second quarter of the fiscal year ending March 2027. The full-year forecast has been revised. The primary drivers of revenue expansion were strengthened global expansion, consolidation of Torii Pharmaceutical, and the transfer of the edaravone business. Indicators such as ROE and ROA also showed improving trends.\n\n### Business Segments and Cost Factors\nContributions were significant from domestic prescription pharmaceuticals, overseas subsidiaries\/exports, and royalty income, with a particularly large increase in royalty income. Although amortization of product-related intangible assets increased, operating income expanded, offsetting increases associated with consolidation of Torii Pharmaceutical and the edaravone business transfer. The full-year forecast will continue to be revised as appropriate.","jir_financial_highlights":"Revenue: 3,504 (YoY: 64.5% increase)\nOperating Income: 1,152 (YoY: 55.8% increase)\nQuarterly Profit: 1,196 (YoY: 44.1% increase)\nEBITDA: 1,746 (YoY: Unknown (see supplemental table))","jir_category":"","jir_hashtags":"#Shionogi_IR_FinancialSummary","jir_key_figures":"Revenue: 3,504\nOperating Income: 1,152\nQuarterly Profit: 1,196","jir_meta_title":"Shionogi & Co., Ltd. \u2014 Supplementary Materials for Q2 FY2027 Financial Results | Revenue 350.4 hundred million yen, Overseas Expansion Contribution","jir_meta_description":"Summary of Shionogi & Co., Ltd.'s supplementary materials for the second quarter of FY2027. Consolidated revenue was 350.4 hundred million yen, operating income 115.2 hundred million yen, and quarterly profit 119.6 hundred million yen. Explains revisions to the full-year forecast and impacts from overseas subsidiaries and the consolidation of Torii Pharmaceutical.","jir_og_title":"Shionogi & Co., Ltd. \u2014 Supplementary Materials for Q2 FY2027 Financial Results | Revenue 350.4 hundred million yen","jir_og_description":"Summary of Shionogi & Co., Ltd.'s Q2 supplementary financial materials. Revenue was 350.4 hundred million yen, operating income 115.2 hundred million yen, and quarterly profit 119.6 hundred million yen. Explains revisions to the full-year forecast and key drivers.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Revenue Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2025-04\\\",\\\"2025-07\\\",\\\"2025-10\\\",\\\"2026-04\\\",\\\"2026-07\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Revenue\\\",\\\"data\\\":[1998,2130,304? ,3504,?],\\\"borderColor\\\":\\\"#3e95cd\\\",\\\"fill\\\":false}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Operating Income Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2025-04\\\",\\\"2025-07\\\",\\\"2025-10\\\",\\\"2026-04\\\",\\\"2026-07\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Income\\\",\\\"data\\\":[351,389,993,1152,?],\\\"borderColor\\\":\\\"#8e5ea2\\\",\\\"fill\\\":false}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Revenue by Segment\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Domestic Prescription Pharmaceuticals\\\",\\\"Overseas Subsidiaries\/Exports\\\",\\\"Royalty Income\\\",\\\"Contract Manufacturing\\\",\\\"OTC Pharmaceuticals\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Revenue\\\",\\\"data\\\":[743,950,1651,66,78],\\\"backgroundColor\\\":\\\"#4dc9f6\\\"}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"margin_analysis\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Gross Margin Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2025-04\\\",\\\"2025-07\\\",\\\"2025-10\\\",\\\"2026-04\\\",\\\"2026-07\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Gross Profit\\\",\\\"data\\\":[875,956,1207,1325,1460],\\\"borderColor\\\":\\\"#36a2eb\\\",\\\"fill\\\":false}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"guidance_comparison\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Full-Year Guidance vs Actuals\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2025-04\\\",\\\"2026-04\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Full-Year Guidance Revenue\\\",\\\"data\\\":[3607,7200],\\\"borderColor\\\":\\\"#ff6384\\\",\\\"fill\\\":false},{\\\"label\\\":\\\"Actual Revenue\\\",\\\"data\\\":[304? ,3504],\\\"borderColor\\\":\\\"#36a2eb\\\",\\\"fill\\\":false}]},\\\"options\\\":{}}\"}]","ir_related_company":6919,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-136026","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n